Clinical Trials

90 trials
RecentStart dateEnrollment
Interventional × Urologic Neoplasms × Genitourinary × Clear all
NCT01552434 2025-10-14

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
155 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

NCT00019630 2024-03-04

Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Completed
CNSGastrointestinalGenitourinaryGynecologicSarcoma

Familial ependymoma, Ovarian Germ Cell Cancer, Astrocytoma, Bone Neoplasms, Brain Neoplasms, Carcinoma, Renal Cell, Endocrine Gland Neoplasms, Gastrointestinal Neoplasms, Carcinoma, Hepatocellular, Medulloblastoma, Meningioma, Neoplasms, Wilms Tumor, Neuroblastoma, Oligodendroglioma, Pinealoma, Osteosarcoma, Teratoma, Testicular Neoplasms, Urologic Neoplasms, Central Nervous System Neoplasms, Choroid Plexus Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Muscle Neoplasms, Optic Nerve Glioma, Genetic Diseases, Inborn, Histiocytoma, Malignant Fibrous

NCT03602079 2023-08-03

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Klus Pharma Inc.

Phase 1/2 Completed
49 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Bile Duct Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Laryngeal Neoplasms, Lip Neoplasms, Liver Neoplasms, Lung Neoplasms, Mouth Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Skin Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Tonsillar Neoplasms, Urologic Neoplasms, Carcinoma, Mucoepidermoid, Cholangiocarcinoma, Rare Diseases

NCT04430842 2023-01-18

Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S

Quadriga Biosciences, Inc.

Phase 1 Completed
15 enrolled
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Sleepiness, Mesothelioma, Malignant, Anorexia, Astrocytoma, Urinary Bladder Neoplasms, Brain Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Head and Neck Neoplasms, Headache, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Seizures, Speech Disorders, Stomach Neoplasms, Thymoma, Tongue Neoplasms, Urologic Neoplasms, Vomiting, Colorectal Neoplasms, Cholangiocarcinoma